• Home
  • Ongoing Clinical Studies

Ongoing Clinical Studies

Filter Clinical Studies by:

Name

Physician(s)

all-types

Name

A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases ›

Physician(s)

Frank A. Vicini, MD
John Vito Antonucci, MD
Michael I. Ghilezan, MD, PhD
Alvaro A. Martinez, MD, FACR

Name

Evaluation of the CytoRADxTM System as a Biodosimeter with Human Subjects Receiving Radiation Therapy ›

Physician(s)

Christopher T. Chen, MD, FACRO
Constantine A. Mantz, MD

Blood

Name

A Disease Registry for Patients with Chronic Lymphocytic Leukemia ›

Physician(s)

Troy H. Guthrie, Jr., MD

Name

Prospective, Longitudinal, Non-Interventional Study Of Disease Burden And Treatment Of Patients With Low-Risk Myelofibrosis (MF) Or High-Risk Essential Thrombocythemia (ET) Or ET Patients Receiving ET-Directed Therapy  ›

Physician(s)

Troy H. Guthrie, Jr., MD

Brain-Cancer

Name

A Randomized, Phase III Trial Of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases ›

Physician(s)

Frank A. Vicini, MD
John Vito Antonucci, MD
Michael I. Ghilezan, MD, PhD
Alvaro A. Martinez, MD, FACR

Breast-Cancer

Name

A Phase IIR/III Trial of Standard of Care with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer ›

Physician(s)

Frank A. Vicini, MD
John Vito Antonucci, MD
Michael I. Ghilezan, MD, PhD
Alvaro A. Martinez, MD, FACR

Name

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy ›

Physician(s)

Frank A. Vicini, MD
John Vito Antonucci, MD
Michael I. Ghilezan, MD, PhD
Alvaro A. Martinez, MD, FACR

Name

MROQC ›

Physician(s)

Larry L. Kestin, MD

Head---Neck-Cancer

Name

Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 651) ›

Physician(s)

Troy H. Guthrie, Jr., MD

Lung-Cancer

Name

A Two-Part, Open-Label, Randomized, Phase II/III Study of Dinutuximab and Irinotecan versus Irinotecan for Second Line Treatment of Subjects with Relapsed or Refractory Small Cell Lung Cancer  ›

Physician(s)

Troy H. Guthrie, Jr., MD

Back
To top